NewAmsterdam Pharma Q3 2026 net loss narrows 76% year over year to USD 17.39 million

Bitget2026/11/04 12:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NewAmsterdam Pharma’s third-quarter 2026 net loss narrowed 76% year over year to $17.39 million.
Revenue rose to $19.16 million from a year earlier, primarily due to regulatory milestones under the Menarini license agreement.
Cash, cash equivalents and marketable securities totaled $643.1 million at September 30, 2026.
European Commission marketing authorizations for Ubeslo and Evlarco marked obicetrapib’s first regulatory approval worldwide.
The PREVAIL interim analysis is planned for fourth-quarter 2026, with results expected in first-quarter 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040730PRIMZONEFULLFEED9869787) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NewAmsterdam Pharma Q3 2026 net loss narrows 76% year over year to USD 17.39 million

You may also like

Crypto prices